Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anavex Life SciencesAVXL -4.47%30 Equity-to-Asset is 0.95 as of Mar. 2026, which is 6% above its 10-year median of 0.90. GuruFocus rates AVXL with a GF Score™ of 30/100. Among 1,415 Biotechnology companies, Anavex Life Sciences ranks better than 92.72% on this metric.
Anavex Life Sciences (NAS:AVXL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Anavex Life Sciences Equity-to-Asset Related Terms
Anavex Life Sciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Anavex Life Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVXL vs OBIO, TARA, TRDA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Anavex Life Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Anavex Life Sciences's Equity to Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (AVXL) has a Equity-to-Asset of 0.95 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Anavex Life Sciences and its competitors. This is near median its historical median of 0.90. Over the past decade, Anavex Life Sciences' Equity-to-Asset has ranged from 0.66 to 0.95. According to the industry distribution chart, Anavex Life Sciences ranks #103 out of 1415 companies in the Biotechnology industry, placing it in the top 7.3%.
Is Anavex Life Sciences' Equity-to-Asset too high?
Anavex Life Sciences' current Equity-to-Asset of 0.95 is near median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 0.95. The Biotechnology industry median Equity-to-Asset is 0.68. Anavex Life Sciences' value of 0.95 is 39.7% above this industry median. Based on the distribution chart, Anavex Life Sciences ranks #103 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Equity-to-Asset compare to OBIO and TARA?
According to the Biotechnology industry distribution chart, Anavex Life Sciences ranks #103 out of 1415 companies for Equity-to-Asset. This places Anavex Life Sciences in the top 7% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.68. Anavex Life Sciences' value of 0.95 is 39.7% above this benchmark. Historically, Anavex Life Sciences' own Equity-to-Asset has ranged from 0.66 to 0.95 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 0.68, Anavex Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anavex Life Sciences's current Equity-to-Asset of 0.95 is 39.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Anavex Life Sciences and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anavex Life Sciences's current Equity-to-Asset is 0.95, which is near median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current Equity-to-Asset of 0.95. The current Equity-to-Asset is 0.95, which is near median its 10-year median of 0.90 and 39.7% above the Biotechnology industry median of 0.68. Anavex Life Sciences' overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current Equity-to-Asset is 0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score
Get the complete analysis for AVXL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVXL has been successfully added to your 
